India | Wisconsin, USA | June 09, 2015 — Cardiac Science Corporation, a group company of Opto Circuits (India) Ltd. (Bloomberg: OPTC IN; Reuters: OPTO. NS; NSE: OPTOCIRCUI; BSE: 532391) and a global leader in automated external defibrillators (AEDs), is celebrating a victory in a long-standing dispute over the company’s wearable defibrillator technology: On May 22, a 12-person jury in Los Angeles Superior Court unanimously decided in favor of the company’s breach of contract claims against Zoll Medical Corporation, and Zoll LifeCor Corporation, awarding Cardiac Science $22,991,985in lost royalties. Cardiac Science was represented by Patterson Thuente IP in the dispute.
Vinod Ramnani, Chairman and Managing Director, Opto Circuits (India) Ltd. stated, “This unanimous jury verdict represents a significant victory for Cardiac Science and the extensive damages validate the significant value ofCardiac Science’s wearable defibrillatortechnology and other technologies in AED space. We will continue our commitment to protect our intellectual property and innovation.”
The dispute relates to the company’s patented wearable defibrillator technology. In 2002, LifeCor began marketing its LifeVest® product, which infringed a number of Cardiac Science’s patents. To avoid infringement claims, LifeCor entered into a cross-license agreement with Cardiac Science and was able to continue selling its device. However, once Zoll Medical acquired Lifecor in 2006, they stopped paying royalties associated with the cross-license agreement. Cardiac Science sued Zoll Medical and Zoll Lifecor, for breach of contract in 2011. CCI Newswire
